NYSEAMERICAN:AIM AIM ImmunoTech Q4 2025 Earnings Report $0.50 -0.02 (-4.26%) As of 12:06 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast AIM ImmunoTech EPS ResultsActual EPS-$0.45Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAIM ImmunoTech Revenue ResultsActual Revenue$0.02 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAIM ImmunoTech Announcement DetailsQuarterQ4 2025Date3/27/2026TimeAfter Market ClosesConference Call DateTuesday, March 31, 2026Conference Call Time8:30AM ETConference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) AIM ImmunoTech Earnings HeadlinesAIM ImmunoTech (AIM) price target decreased by 54.50% to 10.20April 29, 2026 | msn.comAIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and ...April 16, 2026 | markets.businessinsider.comThe Iran War Just Broke the Gold MarketThe Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged… Defense stocks exploded…And gold ripped past $5,000.May 6 at 1:00 AM | Behind the Markets (Ad)AIM ImmunoTech Inc. Reports Audit Findings with Going Concern Emphasis and Positive Clinical Trial Progress for Ampligen in Pancreatic Cancer TreatmentApril 13, 2026 | quiverquant.comQAIM ImmunoTech Provides Routine Update on Annual FilingsApril 13, 2026 | globenewswire.comAIM ImmunoTech Expands At-The-Market Equity Offering CapacityApril 10, 2026 | tipranks.comSee More AIM ImmunoTech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like AIM ImmunoTech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AIM ImmunoTech and other key companies, straight to your email. Email Address About AIM ImmunoTechAIM ImmunoTech (NYSEAMERICAN:AIM) is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments. In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats. AIM ImmunoTech has collaborated with government agencies and academic institutions to support its clinical development, leveraging these partnerships to access specialized expertise and streamline regulatory pathways. Headquartered in Ocala, Florida, AIM ImmunoTech conducts its research and manufacturing operations in the United States, while seeking to establish strategic collaborations that extend its global reach. The company’s management team comprises experienced professionals in biotechnology development, regulatory affairs and commercial strategy, with a shared commitment to bringing novel immunotherapeutic solutions to market. View AIM ImmunoTech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Years in the Making, AMD’s Upside Movement Has Just BegunOld Money, New Tech: Western Union's Crypto RebootPinterest Pins a Profit Play To Its Mood BoardJust How Big a Problem Could Amazon’s Cash Burn Rate Be?BlackBerry Rewrites Its Own Operating SystemGrab Holdings Faces Hurdles, But Upside Potential Is Hard to IgnorePalantir Drops After a Blowout Q1—What Investors Should Know Upcoming Earnings Coinbase Global (5/7/2026)Airbnb (5/7/2026)Datadog (5/7/2026)Ferrovial (5/7/2026)Gilead Sciences (5/7/2026)Microchip Technology (5/7/2026)MercadoLibre (5/7/2026)Monster Beverage (5/7/2026)Canadian Natural Resources (5/7/2026)W.W. Grainger (5/7/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
